KFDA to activate bio-equivalent tests.

Published: 2002-08-28 06:57:00

Updated: 2002-08-28 06:57:00

As a result of the strong government determination on the bio-equivalency issue, the top administrator of KFDA and the director of the Drug Safety Bureau confirmed again to activate the bio-equivalent tests

Dr. Lee Young-soon, the administrator of KFDA and Mr. Chang Joon-shik, the director of...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK